AbbVie reports improved facial satisfaction among weight-loss drug users (ABBV:NYSE)

AbbVie reports improved facial satisfaction among weight-loss drug users (ABBV:NYSE)

AbbVie sees potential Botox and filler demand from GLP-1 users as small studies show improved facial satisfaction after cosmetic treatments.

Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications

– HARMONY IN DIVERSITY is the first study of combined neurotoxin and filler treatment in adults on glucagon-like peptide-1 (GLP-1) medications. In this Phase 4 cohort, participants reported statistically significant improvements in satisfaction with facial appearance and skin quality following…

Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications - PressReach

– HARMONY IN DIVERSITY is the first study of combined neurotoxin and filler treatment in adults on glucagon-like peptide-1 (GLP-1) medications. In this Phase 4 cohort, participants reported statistically significant improvements in satisfaction with facial appearance and skin quality following a treatment regimen that also included skincare– Interim results from HALO, a Phase 4 study … Continue reading "Allergan Aesthetics Reports Improved Satis…